Meridian Bioscience, Inc. Logo

Meridian Bioscience, Inc.

0K0K.L

(0.0)
Stock Price

33,97 USD

-9.11% ROA

0% ROE

-61.83x PER

Market Cap.

1.488.830.434,00 USD

9.14% DER

0% Yield

0% NPM

Meridian Bioscience, Inc. Stock Analysis

Meridian Bioscience, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Meridian Bioscience, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Meridian Bioscience, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Meridian Bioscience, Inc. Technical Stock Analysis
# Analysis Recommendation

Meridian Bioscience, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Meridian Bioscience, Inc. Revenue
Year Revenue Growth
1985 4.900.000
1986 6.300.000 22.22%
1987 5.200.000 -21.15%
1988 5.600.000 7.14%
1989 6.200.000 9.68%
1990 8.500.000 27.06%
1991 11.100.000 23.42%
1992 14.000.000 20.71%
1993 16.200.000 13.58%
1994 21.900.000 26.03%
1995 25.100.000 12.75%
1996 29.400.000 14.63%
1997 35.200.000 16.48%
1998 33.200.000 -6.02%
1999 54.400.000 38.97%
2000 57.096.000 4.72%
2001 56.527.000 -1.01%
2002 59.104.000 4.36%
2003 65.864.000 10.26%
2004 79.606.000 17.26%
2005 92.965.000 14.37%
2006 108.413.000 14.25%
2007 122.963.000 11.83%
2008 139.639.000 11.94%
2009 148.274.000 5.82%
2010 143.000.000 -3.69%
2011 159.723.000 10.47%
2012 173.542.000 7.96%
2013 188.686.000 8.03%
2014 188.832.000 0.08%
2015 194.830.000 3.08%
2016 196.082.000 0.64%
2017 200.771.000 2.34%
2018 213.571.000 5.99%
2019 201.014.000 -6.25%
2020 253.667.000 20.76%
2021 317.896.000 20.2%
2022 333.018.000 4.54%
2023 227.608.000 -46.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Meridian Bioscience, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 1.400.000 100%
1995 1.400.000 0%
1996 1.500.000 6.67%
1997 1.500.000 0%
1998 2.000.000 25%
1999 2.000.000 0%
2000 2.260.000 11.5%
2001 3.363.000 32.8%
2002 2.888.000 -16.45%
2003 3.875.000 25.47%
2004 4.357.000 11.06%
2005 3.821.000 -14.03%
2006 4.799.000 20.38%
2007 6.085.000 21.13%
2008 6.183.000 1.58%
2009 8.428.000 26.64%
2010 8.570.000 1.66%
2011 9.822.000 12.75%
2012 10.275.000 4.41%
2013 10.787.000 4.75%
2014 12.552.000 14.06%
2015 12.605.000 0.42%
2016 13.815.000 8.76%
2017 15.680.000 11.89%
2018 16.870.000 7.05%
2019 17.948.000 6.01%
2020 23.729.000 24.36%
2021 23.911.000 0.76%
2022 24.335.000 1.74%
2023 24.708.000 1.51%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Meridian Bioscience, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 9.100.000 100%
1996 10.400.000 12.5%
1997 11.500.000 9.57%
1998 12.200.000 5.74%
1999 21.000.000 41.9%
2000 23.032.000 8.82%
2001 22.466.000 -2.52%
2002 20.505.000 -9.56%
2003 21.624.000 5.17%
2004 26.660.000 18.89%
2005 30.783.000 13.39%
2006 32.991.000 6.69%
2007 33.825.000 2.47%
2008 35.947.000 5.9%
2009 16.341.000 -119.98%
2010 18.770.000 12.94%
2011 25.431.000 26.19%
2012 27.385.000 7.14%
2013 30.519.000 10.27%
2014 27.389.000 -11.43%
2015 27.616.000 0.82%
2016 30.565.000 9.65%
2017 33.042.000 7.5%
2018 34.488.000 4.19%
2019 34.585.000 0.28%
2020 46.425.000 25.5%
2021 52.344.000 11.31%
2022 57.148.000 8.41%
2023 44.292.000 -29.03%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Meridian Bioscience, Inc. EBITDA
Year EBITDA Growth
1985 2.300.000
1986 2.800.000 17.86%
1987 900.000 -211.11%
1988 700.000 -28.57%
1989 900.000 22.22%
1990 1.700.000 47.06%
1991 2.000.000 15%
1992 3.300.000 39.39%
1993 4.200.000 21.43%
1994 5.600.000 25%
1995 7.900.000 29.11%
1996 11.100.000 28.83%
1997 12.700.000 12.6%
1998 11.000.000 -15.45%
1999 11.000.000 0%
2000 11.749.000 6.38%
2001 -10.160.000 215.64%
2002 11.962.000 184.94%
2003 15.371.000 22.18%
2004 17.272.000 11.01%
2005 23.848.000 27.57%
2006 33.342.000 28.47%
2007 41.081.000 18.84%
2008 50.461.000 18.59%
2009 53.683.000 6%
2010 46.085.000 -16.49%
2011 46.201.000 0.25%
2012 56.313.000 17.96%
2013 62.985.000 10.59%
2014 57.670.000 -9.22%
2015 60.281.000 4.33%
2016 58.168.000 -3.63%
2017 46.189.000 -25.93%
2018 39.824.000 -15.98%
2019 43.466.000 8.38%
2020 75.492.000 42.42%
2021 107.615.000 29.85%
2022 72.017.000 -49.43%
2023 -99.060.000 172.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Meridian Bioscience, Inc. Gross Profit
Year Gross Profit Growth
1985 4.100.000
1986 4.900.000 16.33%
1987 3.600.000 -36.11%
1988 3.800.000 5.26%
1989 4.100.000 7.32%
1990 5.400.000 24.07%
1991 7.500.000 28%
1992 10.000.000 25%
1993 12.200.000 18.03%
1994 16.100.000 24.22%
1995 19.100.000 15.71%
1996 22.600.000 15.49%
1997 25.900.000 12.74%
1998 25.500.000 -1.57%
1999 40.600.000 37.19%
2000 40.257.000 -0.85%
2001 30.706.000 -31.1%
2002 34.598.000 11.25%
2003 38.288.000 9.64%
2004 45.675.000 16.17%
2005 54.820.000 16.68%
2006 64.671.000 15.23%
2007 74.940.000 13.7%
2008 86.480.000 13.34%
2009 92.783.000 6.79%
2010 88.475.000 -4.87%
2011 99.298.000 10.9%
2012 109.878.000 9.63%
2013 121.044.000 9.22%
2014 117.243.000 -3.24%
2015 121.882.000 3.81%
2016 127.787.000 4.62%
2017 124.833.000 -2.37%
2018 130.461.000 4.31%
2019 118.325.000 -10.26%
2020 156.248.000 24.27%
2021 201.148.000 22.32%
2022 188.356.000 -6.79%
2023 126.020.000 -49.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Meridian Bioscience, Inc. Net Profit
Year Net Profit Growth
1985 1.100.000
1986 1.400.000 21.43%
1987 500.000 -180%
1988 200.000 -150%
1989 300.000 33.33%
1990 600.000 50%
1991 1.000.000 40%
1992 1.700.000 41.18%
1993 1.900.000 10.53%
1994 2.400.000 20.83%
1995 3.500.000 31.43%
1996 5.300.000 33.96%
1997 6.000.000 11.67%
1998 5.000.000 -20%
1999 2.400.000 -108.33%
2000 7.111.000 66.25%
2001 -10.275.000 169.21%
2002 5.031.000 304.23%
2003 7.018.000 28.31%
2004 9.185.000 23.59%
2005 12.565.000 26.9%
2006 18.325.000 31.43%
2007 26.721.000 31.42%
2008 30.202.000 11.53%
2009 32.759.000 7.81%
2010 26.647.000 -22.94%
2011 26.831.000 0.69%
2012 33.371.000 19.6%
2013 38.032.000 12.26%
2014 34.743.000 -9.47%
2015 35.540.000 2.24%
2016 32.229.000 -10.27%
2017 21.557.000 -49.51%
2018 23.849.000 9.61%
2019 24.382.000 2.19%
2020 46.186.000 47.21%
2021 71.407.000 35.32%
2022 42.459.000 -68.18%
2023 -119.284.000 135.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Meridian Bioscience, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 100%
2021 2 0%
2022 1 0%
2023 -3 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Meridian Bioscience, Inc. Free Cashflow
Year Free Cashflow Growth
1990 600.000
1991 100.000 -500%
1992 -700.000 114.29%
1993 1.400.000 150%
1994 2.900.000 51.72%
1995 400.000 -625%
1996 3.700.000 89.19%
1997 4.900.000 24.49%
1998 5.600.000 12.5%
1999 -12.300.000 145.53%
2000 1.170.000 1151.28%
2001 6.779.000 82.74%
2002 7.865.000 13.81%
2003 10.541.000 25.39%
2004 10.268.000 -2.66%
2005 15.597.000 34.17%
2006 18.913.000 17.53%
2007 23.126.000 18.22%
2008 24.556.000 5.82%
2009 28.739.000 14.56%
2010 26.530.000 -8.33%
2011 13.305.000 -99.4%
2012 37.611.000 64.62%
2013 41.159.000 8.62%
2014 31.260.000 -31.67%
2015 38.045.000 17.83%
2016 33.219.000 -14.53%
2017 36.888.000 9.95%
2018 30.582.000 -20.62%
2019 32.034.000 4.53%
2020 44.677.000 28.3%
2021 48.553.000 7.98%
2022 73.746.000 34.16%
2023 -5.003.000 1574.04%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Meridian Bioscience, Inc. Operating Cashflow
Year Operating Cashflow Growth
1990 800.000
1991 1.000.000 20%
1992 1.300.000 23.08%
1993 2.100.000 38.1%
1994 4.400.000 52.27%
1995 2.900.000 -51.72%
1996 4.900.000 40.82%
1997 6.500.000 24.62%
1998 6.900.000 5.8%
1999 9.000.000 23.33%
2000 5.217.000 -72.51%
2001 8.702.000 40.05%
2002 11.415.000 23.77%
2003 12.353.000 7.59%
2004 12.653.000 2.37%
2005 18.187.000 30.43%
2006 22.155.000 17.91%
2007 26.602.000 16.72%
2008 29.883.000 10.98%
2009 32.492.000 8.03%
2010 31.213.000 -4.1%
2011 22.456.000 -39%
2012 42.446.000 47.1%
2013 44.436.000 4.48%
2014 38.262.000 -16.14%
2015 42.809.000 10.62%
2016 37.223.000 -15.01%
2017 41.355.000 9.99%
2018 34.783.000 -18.89%
2019 35.831.000 2.92%
2020 47.976.000 25.31%
2021 66.865.000 28.25%
2022 82.361.000 18.81%
2023 -2.349.000 3606.22%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Meridian Bioscience, Inc. Capital Expenditure
Year Capital Expenditure Growth
1990 200.000
1991 900.000 77.78%
1992 2.000.000 55%
1993 700.000 -185.71%
1994 1.500.000 53.33%
1995 2.500.000 40%
1996 1.200.000 -108.33%
1997 1.600.000 25%
1998 1.300.000 -23.08%
1999 21.300.000 93.9%
2000 4.047.000 -426.32%
2001 1.923.000 -110.45%
2002 3.550.000 45.83%
2003 1.812.000 -95.92%
2004 2.385.000 24.03%
2005 2.590.000 7.92%
2006 3.242.000 20.11%
2007 3.476.000 6.73%
2008 5.327.000 34.75%
2009 3.753.000 -41.94%
2010 4.683.000 19.86%
2011 9.151.000 48.83%
2012 4.835.000 -89.27%
2013 3.277.000 -47.54%
2014 7.002.000 53.2%
2015 4.764.000 -46.98%
2016 4.004.000 -18.98%
2017 4.467.000 10.36%
2018 4.201.000 -6.33%
2019 3.797.000 -10.64%
2020 3.299.000 -15.1%
2021 18.312.000 81.98%
2022 8.615.000 -112.56%
2023 2.654.000 -224.6%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Meridian Bioscience, Inc. Equity
Year Equity Growth
1985 1.600.000
1986 7.300.000 78.08%
1987 7.800.000 6.41%
1988 8.000.000 2.5%
1989 8.300.000 3.61%
1990 9.000.000 7.78%
1991 9.500.000 5.26%
1992 10.700.000 11.21%
1993 11.600.000 7.76%
1994 13.200.000 12.12%
1995 18.900.000 30.16%
1996 29.600.000 36.15%
1997 32.600.000 9.2%
1998 34.700.000 6.05%
1999 33.900.000 -2.36%
2000 36.611.000 7.4%
2001 22.944.000 -59.57%
2002 24.381.000 5.89%
2003 27.484.000 11.29%
2004 32.932.000 16.54%
2005 83.768.000 60.69%
2006 94.777.000 11.62%
2007 112.948.000 16.09%
2008 128.489.000 12.1%
2009 137.905.000 6.83%
2010 137.361.000 -0.4%
2011 138.524.000 0.84%
2012 142.748.000 2.96%
2013 155.045.000 7.93%
2014 161.029.000 3.72%
2015 165.873.000 2.92%
2016 166.472.000 0.36%
2017 169.585.000 1.84%
2018 175.418.000 3.33%
2019 190.967.000 8.14%
2020 247.629.000 22.88%
2021 328.302.000 24.57%
2022 368.061.000 10.8%
2023 340.539.000 -8.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Meridian Bioscience, Inc. Assets
Year Assets Growth
1985 3.100.000
1986 9.000.000 65.56%
1987 9.200.000 2.17%
1988 9.000.000 -2.22%
1989 9.400.000 4.26%
1990 10.600.000 11.32%
1991 11.000.000 3.64%
1992 14.100.000 21.99%
1993 26.200.000 46.18%
1994 32.300.000 18.89%
1995 34.600.000 6.65%
1996 56.500.000 38.76%
1997 57.500.000 1.74%
1998 59.100.000 2.71%
1999 72.400.000 18.37%
2000 84.769.000 14.59%
2001 65.982.000 -28.47%
2002 65.095.000 -1.36%
2003 66.420.000 1.99%
2004 69.322.000 4.19%
2005 110.569.000 37.3%
2006 120.955.000 8.59%
2007 132.698.000 8.85%
2008 146.431.000 9.38%
2009 155.997.000 6.13%
2010 154.785.000 -0.78%
2011 155.493.000 0.46%
2012 161.381.000 3.65%
2013 176.748.000 8.69%
2014 176.929.000 0.1%
2015 183.282.000 3.47%
2016 251.823.000 27.22%
2017 249.777.000 -0.82%
2018 251.377.000 0.64%
2019 325.478.000 22.77%
2020 405.261.000 19.69%
2021 449.722.000 9.89%
2022 463.097.000 2.89%
2023 456.763.000 -1.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Meridian Bioscience, Inc. Liabilities
Year Liabilities Growth
1985 1.500.000
1986 1.700.000 11.76%
1987 1.400.000 -21.43%
1988 1.000.000 -40%
1989 1.100.000 9.09%
1990 1.600.000 31.25%
1991 1.500.000 -6.67%
1992 3.400.000 55.88%
1993 14.600.000 76.71%
1994 19.100.000 23.56%
1995 15.700.000 -21.66%
1996 26.900.000 41.64%
1997 24.900.000 -8.03%
1998 24.400.000 -2.05%
1999 38.500.000 36.62%
2000 48.158.000 20.05%
2001 43.038.000 -11.9%
2002 40.714.000 -5.71%
2003 38.936.000 -4.57%
2004 36.390.000 -7%
2005 26.801.000 -35.78%
2006 26.178.000 -2.38%
2007 19.750.000 -32.55%
2008 17.942.000 -10.08%
2009 18.092.000 0.83%
2010 17.424.000 -3.83%
2011 16.969.000 -2.68%
2012 18.633.000 8.93%
2013 21.703.000 14.15%
2014 15.900.000 -36.5%
2015 17.409.000 8.67%
2016 85.351.000 79.6%
2017 80.192.000 -6.43%
2018 75.959.000 -5.57%
2019 134.511.000 43.53%
2020 157.632.000 14.67%
2021 121.420.000 -29.82%
2022 95.036.000 -27.76%
2023 116.224.000 18.23%

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Meridian Bioscience, Inc. Dividends
Year Dividends Growth
2018 0
2019 0 0%

Meridian Bioscience, Inc. Profile

About Meridian Bioscience, Inc.

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

CEO
Mr. John P. Kenny
Employee
690
Address
3471 River Hills Drive
Cincinnati, 45244

Meridian Bioscience, Inc. Executives & BODs

Meridian Bioscience, Inc. Executives & BODs
# Name Age
1 Mr. Emerson C. Moser
Senior Vice President & Gen. Counsel
70
2 Ms. Julie Smith
Senior Vice President, Controller & Principal Accounting Officer
70
3 Mr. Jeff Pinkston
Director of Corporation Fin.
70
4 Ms. Susan D. Rolih
Consultant
70
5 Mr. Andrew S. Kitzmiller
Executive Vice President & Chief Financial Officer
70
6 Mr. Charles Wood
Vice President of Corporation Strategy, Bus. Devel. & Investor Relations
70
7 Ms. Melissa A. Lueke
Consultant
70
8 Dr. Lourdes G. Weltzien Ph.D.
Executive Vice President of Life Science Bus. Unit
70
9 Ms. Melissa J. McCarey
Vice President of Global HR
70
10 Mr. John P. Kenny
Pres, Chief Executive Officer & Director
70
11 Mr. Tony Serafini-Lamanna
Executive Vice President of Diagnostics
70

Meridian Bioscience, Inc. Competitors